JIANGANLING LAMIVUDINE TABLETS For Hepatitis 0.1g*14 Tablets*5 boxes

拉米夫定片

Generic name: Lamivudine tablets
Chinese Pinyin: LaMiFuDingPian
English name: Lamivudine Tablets
Product name: Jian Gan Ling
Ingredients: The main ingredient of this product is lamivudine.
Properties: This product is orange-yellow film-coated tablets, white after removing the film coating.
Indications: Lamivudine tablets are suitable for the treatment of adult chronic hepatitis B patients with compensatory liver function accompanied by elevated alanine aminotransferase [ALT] and replication of viral activity.
Specification: 0.1g*14pcs/box
Usage and dosage: Oral. 1. This product should be used under the guidance of a doctor experienced in the treatment of chronic hepatitis B. The recommended dosage is 0.1g (1 tablet) once a day, either before or after meals.
Adverse reactions: Common adverse reactions include upper respiratory tract infection-like symptoms, headache, nausea, physical discomfort, abdominal pain and diarrhea. The symptoms are generally mild and can relieve themselves.
Taboo: People who are allergic to this product should not be used.
Note: 1. During the treatment period, the patient's clinical condition and virological indicators should be checked regularly. 2. After a few patients stop using this product, hepatitis may get worse. Therefore, if you stop using this product, you should closely observe the patient. If hepatitis worsens, you should consider reusing this product for treatment. 3. Patients with renal insufficiency will affect the excretion of lamivudine. For patients whose creatinine clearance rate is less than 30ml/min, this product is not recommended. Liver damage does not affect the drug metabolism of lamivudine. 4. During the treatment with this product, the patient cannot prevent the hepatitis B virus from infecting others through sexual contact or blood-borne transmission, so appropriate protective measures should still be taken. 5. There is no data to show that pregnant women can suppress the mother-to-child transmission of hepatitis B virus after taking this product. Therefore, neonates should still be immunized against hepatitis B routinely.
Drug interactions: 1. When lamivudine is used simultaneously with drugs with the same excretion mechanism (such as trimethoprim, sulfamethazole), the blood concentration of lamivudine can increase by 40%, which has no clinical significance, but it has kidneys Patients with functional impairment should pay attention. 2. Combination with zidovudine can increase the latter's peak plasma concentration (Cmax), but does not affect the elimination of the two and the area under the drug-time curve.
Pharmacology and Toxicology: Lamivudine is a nucleoside antiviral drug. It has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and experimentally infected animals. Lamivudine can be metabolized in HBV-infected cells and normal cells to produce lamivudine triphosphate. It is the active form of lamivudine, which is not only an inhibitor of HBV polymerase, but also a substrate of this polymerase. Lamivudine triphosphate penetrates into the viral DNA chain and blocks the synthesis of viral DNA. Lamivudine triphosphate does not interfere with the metabolism of deoxynucleosides in normal cells. It has weak inhibitory effect on mammalian DNA polymerase a and b, and has almost no effect on the DNA content of mammalian cells. Lamivudine has no obvious toxicity to the structure, DNA content and function of mitochondria. The test results of serum HBV DNA in most patients with hepatitis B show that lamivudine can quickly inhibit HBV replication, and its inhibitory effect continues throughout the treatment process, while reducing serum aminotransferase to normal.
Overdose: There are no special signs and symptoms of overdose. If an overdose occurs, the patient should be monitored and given routine supportive therapy. Lamivudine can be eliminated by hemodialysis.
Storage: shading, sealed and stored.
Packaging: Aluminum-plastic packaging, 14 pieces/board×1 board/box.
Validity period: 24 months
Approval number: National Medicine Standard H120103481
Company Name: Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd.